Position
Fidelity in Recursion Pharmaceuticals In
Back to the book · All holders of RECURSION PHARMACEUTICALS IN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $27.8K$3.07 → $3.67
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 3.24M | $13.3M | — | — | — | 0.0% |
| Q1 2026 | 736.7K | $2.26M | $3.07 | −$751.4K | −$10.2M | 0.0% |
| Q2 2026 | 46.4K | $170.1K | $3.67 | $27.8K | −$2.12M | 0.0% |